DELRAY BEACH, Fla., May 31, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it received a notification from the NASDAQ Hearings Department on May 27, 2011, that a Hearings Panel has granted the Company an extension to regain compliance with the minimum bid price requirement set forth in NASDAQ Marketplace Rule 5550(a)(2): 180 days from March 15, 2011, the date the Company received a determination letter regarding the minimum bid price deficiency.
